WHO Approves First Malaria Medicine for Babies
WHO Approves First Malaria Medicine for Babies
Introduction
The World Health Organization (WHO) gave a special approval for a new malaria medicine. This medicine is for newborn babies and infants. It is the first time the WHO did this. The decision was on April 24. The medicine is called artemether-lumefantrine.
Main Body
The approval means the medicine is safe and works well. Before, babies got medicine for older children. That was dangerous. It could cause wrong doses and bad side effects. Malaria is a big problem. In 2024, there were 282 million cases and 610,000 deaths. Most cases and deaths are in Africa. Children under five years old are three-quarters of the deaths. Progress is slow because of drug resistance, insecticide resistance, and less money from other countries. This new medicine will help about 30 million babies born each year in Africa. Many countries cannot check medicines well. The WHO program makes sure medicines are good for use around the world. The WHO director said malaria hurt many children. New tools like vaccines and this medicine help. He thinks we can end malaria if we keep working and spending money.
Conclusion
This approval helps protect the youngest children from malaria. It fills a big need. But the WHO says we need more money and better systems to stop malaria completely.
Vocabulary Learning
Sentence Learning
WHO Grants First Prequalification Approval for Infant-Specific Malaria Treatment
Introduction
The World Health Organization has granted prequalification approval to a new antimalarial formulation designed specifically for newborns and infants, marking a first in the agency's history. The decision, announced on April 24, applies to the drug artemether-lumefantrine.
Main Body
The WHO stated that the prequalification status confirms the medicine meets international standards of quality, safety, and efficacy. Artemether-lumefantrine is the first antimalarial product made specifically for the youngest patients of the mosquito-borne disease. Previously, infants received treatments intended for older children, a practice that had a higher risk of dosage errors, side effects, and toxicity. The importance of this development is clear from the global situation. According to WHO data from 2024, there were an estimated 282 million malaria cases and 610,000 deaths across 80 countries. Africa accounts for 95 percent of both cases and deaths, with children under five representing three-quarters of those deaths. The WHO noted that progress against malaria is hindered by drug resistance, insecticide resistance, diagnostic failures, and large cuts in foreign aid spending. The prequalification approval is expected to help public sector purchases and address a long-term treatment gap for approximately 30 million infants born each year in malaria-endemic regions of Africa. Furthermore, globally, 70 percent of countries lack strong regulatory systems to oversee medicines, vaccines, tests, and medical devices. The WHO prequalification program ensures that key health products for international procurement meet global standards for quality, safety, efficacy, and performance. WHO Director-General Tedros Adhanom Ghebreyesus spoke about this milestone. He noted that malaria has historically caused a lot of harm to children and communities. He stated that new vaccines, diagnostic tests, next-generation mosquito nets, and effective medicines—including those adapted for the youngest—are helping to change the direction of the disease. He further asserted that ending malaria within the current generation is a realistic goal, but it depends on continued political and financial commitment.
Conclusion
This prequalification approval is a specific action to reduce the risk of illness and death from malaria among the most vulnerable group. While the measure addresses an important lack of treatment, the WHO emphasizes that continued investment and improvements to the system are necessary to keep making progress toward eliminating malaria.
Vocabulary Learning
Sentence Learning
WHO Grants First Prequalification Approval for Infant-Specific Malaria Treatment
Introduction
The World Health Organization has granted prequalification approval to a novel antimalarial formulation designed specifically for newborns and infants, marking a first in the agency's history. The decision, announced on April 24, applies to the drug artemether-lumefantrine.
Main Body
The prequalification designation, as stated by the WHO, confirms that the medicine meets international standards of quality, safety, and efficacy. Artemether-lumefantrine is the first antimalarial product formulated explicitly for the youngest victims of the mosquito-borne disease. Previously, infants received treatments intended for older children, a practice that carried a higher risk of dosage errors, adverse side effects, and toxicity. The broader epidemiological context underscores the significance of this development. According to WHO data from 2024, there were an estimated 282 million malaria cases and 610,000 deaths across 80 countries. Africa accounts for 95 percent of both cases and fatalities, with children under five representing three-quarters of those deaths. The WHO noted that progress against malaria is impeded by drug resistance, insecticide resistance, diagnostic failures, and sharp reductions in foreign aid spending. The prequalification approval is expected to facilitate public sector procurement and help address a longstanding treatment gap for approximately 30 million infants born annually in malaria-endemic regions of Africa. Globally, 70 percent of countries lack regulatory systems robust enough to oversee medicines, vaccines, tests, and medical devices. The WHO prequalification program ensures that key health products for international procurement adhere to global benchmarks for quality, safety, efficacy, and performance. WHO Director-General Tedros Adhanom Ghebreyesus commented on the milestone, noting that malaria has historically caused significant harm to children and communities. He stated that new vaccines, diagnostic tests, next-generation mosquito nets, and effective medicines—including those adapted for the youngest—are contributing to a shift in the trajectory of the disease. He further asserted that ending malaria within the current generation is a realistic objective, contingent upon sustained political and financial commitment.
Conclusion
This prequalification approval represents a targeted intervention to reduce the risk of malaria-related morbidity and mortality among the most vulnerable demographic. While the measure addresses a critical treatment gap, the WHO emphasizes that continued investment and systemic improvements are necessary to sustain progress toward malaria elimination.